Neurogen Commences Human Testing of Obesity Drug
Posted on: Monday, 13 November 2006, 15:01 CST
Neurogen Corporation has commenced phase I human testing of its leading drug candidate NGD-4715, for the treatment of obesity.
The phase I trial is an evaluation in healthy overweight and obese subjects of the safety, pharmacokinetics, and pharmacodynamics of single rising oral doses of NGD-4715. The study has a planned total enrollment of up to 84 male and female subjects.
"While the MCH1 mechanism has been a target of high interest in the pharmaceutical community, we believe most in the industry have encountered significant obstacles to advancing drug candidates into human studies," stated William Koster, president and CEO.
Neurogen's obesity program is focused on blocking the melanin concentrating hormone receptor-1 (MCH1). Reported studies in rodents support MCH being an important mediator of caloric intake. Deletion of MCH or the MCH1 receptor gene resulted in lean animals, while over-production of MCH caused increased weight gain. The company's studies indicated that selectively blocking MCH1 was sufficient to achieve a significant reduction in food intake in a higher animal species.
Source: Datamonitor
Related Articles
- Neurogen Completes Ascending Dose Obesity Studies
- Neurogen Announces Results of Multiple Ascending Dose Studies With Experimental Obesity Drug
- New Joslin-Led Study Uncovers Role of Appetite-Related Melanin Concentrating Hormone (MCH) in the Brain to Beta Cell Growth and Insulin Secretion
- The State of Elementary Social Studies Teaching in One Urban District
- Portraits of Practices in Social Studies Methods Courses
- Impact of a High School Graduation Examination on Social Studies Teachers' Instructional Practices
- Ancient oceans lacked oxygen essential for life, study shows
- Antidepressant Study Needs Mexican Volunteers
- Bear Study May Aid Osteoporosis Research
- Alzheimer's Studies Look at Role of Fats
 |
 |
User Comments (0)
RSS Feeds